How Can I Stay Up to Date on Medication Shortages? | Calibrate

Why GLP-1 Medication Shortages Happen

GLP-1 receptor agonists face a supply-demand mismatch that is unlike almost any other drug class. Demand for semaglutide and tirzepatide grew faster than manufacturers could scale fill-and-finish capacity, driving multi-year shortage listings. Understanding the mechanics helps you anticipate future gaps.

Demand Outpaced Manufacturing Capacity

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [1]. Those results, published in the New England Journal of Medicine in 2021, triggered a surge in prescribing that Novo Nordisk's manufacturing lines could not immediately absorb [1]. Tirzepatide followed a similar arc: the SURMOUNT-1 trial (N=2,539) reported up to 22.5% mean weight loss at 72 weeks, accelerating demand before Eli Lilly had fully expanded capacity [2].

Regulatory Shortage Declarations

The FDA declares a shortage when the agency determines that the total supply of all clinically interchangeable versions of a drug is inadequate to meet current or projected demand [3]. Once declared, the shortage is posted publicly in the FDA Drug Shortages Database within 72 hours. That database is the definitive legal record. Secondary sources including news articles and social media frequently lag or misrepresent the FDA's current status [3].

Impact on Compounding Pharmacies

During an active FDA shortage, 503A compounding pharmacies (serving individual patients) and 503B outsourcing facilities (serving health systems) may legally produce copies of the shortage drug [4]. The FDA confirmed this permission for semaglutide in a guidance document posted at fda.gov in 2023 [4]. When the FDA removes a drug from the shortage list, that compounding window closes, typically with a 60-to-90-day wind-down period for patient transitions [4].

The FDA Drug Shortages Database: Your Primary Tool

The FDA Drug Shortages Database is the single most authoritative real-time source for shortage status. It is maintained by the FDA's Center for Drug Evaluation and Research and is updated continuously [3].

How to Search the Database

1. Go to accessdata.fda.gov/scripts/drugshortages [3].
2. Type the generic name (e.g., "semaglutide" or "tirzepatide") in the search field.
3. Review the status column: "Current," "Resolved," or "Discontinued."
4. Click the drug name to see lot-specific notes, affected manufacturers, and the date of last update.

The database does not require an account. Bookmark it directly. Checking two weeks before your refill date gives you time to act on any new listing [3].

Reading the Shortage Detail Page

Each shortage record lists the reason (e.g., increased demand, raw material issue), the firms affected, and any FDA actions taken to mitigate supply [3]. The FDA's Drug Shortage Staff also publishes an annual report summarizing shortage trends; the 2022 report identified biologics and injectables as the fastest-growing shortage category [5].

Email Alerts from FDA

The FDA does not currently offer a direct email subscription specifically for the Drug Shortages Database. Sign up for the FDA's MedWatch Safety Alerts at fda.gov/safety/medwatch to receive broader drug safety and availability communications [6].

ASHP Drug Shortage Resource Center

The American Society of Health-System Pharmacists (ASHP) maintains a parallel shortage database that often includes clinical guidance the FDA page does not [7]. Pharmacists at health systems rely on ASHP data when making substitution decisions [7].

What ASHP Adds Beyond the FDA

ASHP shortage bulletins include shortage-specific clinical recommendations, suggested alternative agents, and estimated resolution timelines contributed by manufacturer representatives [7]. For semaglutide, ASHP published a bulletin recommending that clinicians document medical necessity and contact their wholesaler's shortage desk directly [7].

How to Set Up ASHP Alerts

Manage to ashp.org/drug-shortages and use the "Subscribe" option to receive email notifications when a shortage record for a specific drug is created or updated [7]. This is free and does not require an ASHP membership.

Calibrate-Specific Shortage Tracking

Calibrate's clinical team monitors shortage databases daily and pushes in-app notifications to affected members before their next scheduled refill. Here is what to expect from that system and what you can do on your end.

The Calibrate Patient Portal

Your Calibrate portal dashboard includes a medication status section that reflects the current dispensing status of your prescribed agent. When a shortage affects your specific medication and dose, a banner alert appears at least 14 days before your refill is due. Log in at least every two weeks to catch these alerts early [8].

The HealthRX editorial team developed the following patient-action framework based on the FDA shortage declaration timeline and Calibrate's internal refill cycle data. Use it as a personal shortage-response checklist.

Calibrate Patient Shortage-Response Framework

| Days Before Refill | Action | |---|---| | 30+ days out | Check FDA database; confirm no shortage listing for your drug | | 14-30 days out | Log into Calibrate portal; review medication status banner | | 7-14 days out | Contact Calibrate care team if portal shows shortage alert | | 3-7 days out | Ask care team about bridging dose or alternative agent | | 0-3 days out | Request emergency supply authorization if clinically appropriate |

Messaging Your Calibrate Care Team

Send a secure message through the portal rather than calling a general line. Include your current medication name, dose, and the date your supply runs out. The care team can file a shortage accommodation request with the dispensing pharmacy on your behalf within one business day [8].

Alternative Agents During Shortage

If semaglutide is unavailable, your Calibrate clinician may discuss tirzepatide (if in stock), liraglutide 3.0 mg (Saxenda), or oral semaglutide (Rybelsus 7 mg or 14 mg) depending on your clinical profile [9]. The 2023 American Diabetes Association Standards of Care note that GLP-1 receptor agonists as a class share mechanistic properties, though efficacy magnitudes differ across agents [9]. Switching agents requires a new prior authorization in most cases, so starting that process 30 days early is advisable.

Pharmacy-Level Shortage Tracking

Your dispensing pharmacy is a frontline resource. Most national chains now offer structured shortage notification systems.

Retail Chain Pharmacy Alerts

CVS, Walgreens, and Walmart Pharmacy each offer free SMS text alerts when a prescription cannot be filled due to a shortage. Opt in through the pharmacy's mobile app or by asking the pharmacist to add your phone number to their notification preference system [10]. These alerts are specific to your prescription and your chosen pharmacy location, making them more personally relevant than a national database search [10].

Specialty and Mail-Order Pharmacies

Calibrate works with specialty mail-order pharmacies that have dedicated shortage-management pharmacists. These pharmacists contact the prescribing clinician directly when a dispense cannot be completed, rather than simply returning the prescription to the patient [11]. Specialty pharmacies also have access to wholesaler allocation data that retail pharmacies do not, which means they may identify a shortage 24 to 48 hours before it appears in the FDA database [11].

Independent Pharmacy Networks

Independent pharmacies that belong to buying groups such as the PBA Health network sometimes receive manufacturer shortage notices directly, ahead of the public FDA posting. If you use an independent pharmacy, ask the pharmacist whether they subscribe to any shortage notification service from their buying group [12].

CDC and NIH Resources for Shortage Information

The CDC publishes shortage bulletins when supply disruptions affect public health programs, including obesity treatment initiatives and diabetes prevention programs [13]. The NIH National Library of Medicine's DailyMed database at dailymed.nlm.nih.gov lists current labeling for all FDA-approved drugs and can confirm whether a product has been discontinued entirely versus temporarily shorted [14].

CDC Shortage Bulletins

The CDC's pharmacy and clinical resources page at cdc.gov/vaccines/programs/vfc/providers/pharmacy-resources.html focuses primarily on vaccines, but the broader CDC Health Alert Network (HAN) issues advisories when drug shortages intersect with public health priorities [13]. Sign up for HAN alerts at emergency.cdc.gov/han [13].

DailyMed for Discontinuation vs. Shortage

A shortage means temporary unavailability. A discontinuation means the manufacturer has withdrawn the product permanently [14]. The DailyMed record will show "Discontinued" in the marketing status field if a product has been pulled [14]. Checking DailyMed alongside the FDA shortage database prevents confusion when a specific formulation (e.g., a particular pen device) is discontinued while the drug itself remains available in another form.

Compounding Semaglutide: What the Shortage Status Means for You

During the period when semaglutide was listed as a shortage drug, FDA permitted 503A and 503B compounders to produce semaglutide copies [4]. The FDA removed tirzepatide from the shortage list in October 2024 and began the process of removing semaglutide in early 2025, with a phased wind-down to protect patients mid-treatment [4].

The 60-Day Wind-Down Rule

FDA guidance issued in 2025 gave 503A pharmacies 60 days and 503B facilities 90 days to transition patients off compounded semaglutide once the drug was removed from the shortage list [4]. If you are currently on a compounded GLP-1, monitor the FDA shortage list closely. A removal from the list starts that countdown, even if your pharmacy has not contacted you yet [4].

Verifying Your Pharmacy's Legal Status

The FDA maintains a list of registered 503B outsourcing facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities [15]. Check that your compounding pharmacy appears on this list if you are receiving compounded semaglutide or tirzepatide. Facilities not on this list are not authorized to compound for interstate distribution [15].

Red Flags in Compounded GLP-1 Products

The FDA issued warning letters in 2024 to compounders adding unauthorized ingredients such as cyanocobalamin (B12), carnitine, and glutamine to compounded semaglutide [16]. These additives are not FDA-approved components of semaglutide and carry unknown interaction profiles [16]. The FDA's warning letter database at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters lists sanctioned facilities by name [16].

Building a Personal Shortage-Monitoring Routine

Staying ahead of a shortage requires a short weekly habit rather than a single annual check. This section outlines a practical monitoring cadence.

Weekly Two-Minute Check

Every Monday, spend two minutes on three tasks: (1) open the FDA Drug Shortages Database and search your medication name; (2) log into your Calibrate portal and review the medication status section; (3) check your pharmacy app for any pending alerts. That three-step habit catches most shortage developments before they affect your supply [3].

Setting Calendar Reminders

Set a recurring calendar reminder 30 days before each expected refill date. Label it "Refill shortage check." On that day, run the full search sequence above and, if a shortage is active, message your Calibrate care team immediately [8]. The 30-day buffer is enough time to complete a prior authorization for an alternative agent if needed [9].

Joining Patient Community Forums

Online communities such as the r/Ozempic and r/WeightLossAdvice subreddits frequently surface anecdotal shortage reports 48 to 72 hours before official FDA postings, because patients encounter empty pharmacy shelves before the FDA's reporting cycle catches up. Treat these reports as an early warning signal only, not a confirmed shortage. Always verify against the FDA database before taking clinical action [3].

What Your Clinician Can Do During a Shortage

Your prescribing clinician has tools unavailable to you directly. Knowing what to ask for speeds up shortage resolution.

Prior Authorization Expediting

Most commercial insurers have an expedited prior authorization pathway specifically for shortage situations. Your clinician can file a "shortage exception" request citing the FDA database listing [17]. Turnaround on these requests can be as short as 24 hours versus the standard 5-to-10-business-day review [17].

Manufacturer Patient Assistance Programs

Novo Nordisk's NovoCare program and Eli Lilly's LillyConnect program provide direct-to-patient supply options during shortage periods for eligible patients [18]. Your clinician can submit a referral. Eligibility typically requires documentation of commercial insurance denial or shortage-driven dispense failure [18]. The Endocrine Society's 2023 clinical practice guidelines on obesity pharmacotherapy specifically recommend that clinicians document shortage-related dispense failures to support these applications [19].

As the Endocrine Society 2023 guidelines state: "Clinicians should proactively counsel patients about potential supply interruptions and establish contingency medication plans before a shortage affects their treatment continuity" [19].

Step Therapy Overrides

If your insurer requires step therapy (trying a less expensive agent before the preferred drug), a documented shortage of the preferred agent often qualifies as a step therapy override [17]. Ask your Calibrate clinician to include the FDA shortage database URL and date in any override letter [17].

Interpreting Shortage News in the Media

Media reporting on GLP-1 shortages is frequently inaccurate, outdated, or conflated across different drugs and formulations. A headline reading "Ozempic shortage resolved" may refer only to the 0.5 mg dose, not the 1.0 mg dose you use [20].

Dose-Specific vs. Drug-Wide Shortages

The FDA shortage database entry for semaglutide injection covered specific presentations (pen injectors at particular doses) rather than the entire drug class [3]. Verify the specific NDC (National Drug Code) of your prescribed formulation against the shortage record. Your pharmacy can provide your NDC [14].

Manufacturer Press Releases Are Not FDA Declarations

Novo Nordisk and Eli Lilly issue press releases announcing production milestones and expanded supply. These are company statements, not FDA shortage resolutions. A shortage is only officially resolved when the FDA updates the database status to "Resolved" [3]. A Journal of the American Medical Association analysis of the 2022-2023 semaglutide shortage found that manufacturer supply announcements preceded actual FDA resolution by a median of 11 weeks, meaning patients who acted on press releases often encountered ongoing dispense failures [20].

Special Populations: Diabetes vs. Weight Management Indications

The shortage management pathway differs depending on whether your GLP-1 is prescribed for type 2 diabetes or chronic weight management, because the approved products and insurance coverage rules differ.

Type 2 Diabetes Patients

Ozempic (semaglutide 0.5 mg, 1.0 mg, 2.0 mg) is FDA-approved for type 2 diabetes glycemic control [21]. During an Ozempic shortage, your endocrinologist or primary care physician may transition you to dulaglutide (Trulicity), exenatide extended-release (Bydureon BCise), or insulin-based regimens. The American Diabetes Association's 2024 Standards of Care recommend maintaining glycemic targets during any agent transition and increasing monitoring frequency to every two weeks [9].

Chronic Weight Management Patients

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 2.5 mg through 15 mg) are FDA-approved specifically for chronic weight management in adults with BMI <30 or BMI <27 with at least one weight-related comorbidity [22]. During a Wegovy shortage, oral semaglutide (Rybelsus) is not a like-for-like substitute because its bioavailability is approximately 1% versus subcutaneous semaglutide, producing meaningfully lower systemic exposure at approved doses [23]. Your Calibrate clinician can calculate a dose-equivalent bridging plan if a transition is necessary [23].

Staying Informed: A Source Priority Hierarchy

Not all shortage sources carry equal weight. Use this hierarchy to decide how to act on information you encounter.

Tier 1 (Act immediately): FDA Drug Shortages Database shows "Current" status for your medication [3].

Tier 2 (Verify and prepare): ASHP Drug Shortage bulletin published for your medication [7].

Tier 3 (Monitor closely): Calibrate portal banner or care team message about your prescription [8].

Tier 4 (Early warning only): Pharmacy SMS alert or wholesaler communication [10].

Tier 5 (Verify before acting): Media reports, manufacturer press releases, patient forum posts [20].

Work through this hierarchy in order. Do not skip Tier 1 verification regardless of how credible a lower-tier source seems.